Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

Volume: 20, Issue: 21, Pages: 5399 - 5399
Published: Oct 30, 2019
Abstract
Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory recurrent/metastatic (R/M) HNSCC. Furthermore, checkpoint inhibitors are better tolerated than chemotherapy. The state of the art in the treatment of...
Paper Details
Title
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
Published Date
Oct 30, 2019
Volume
20
Issue
21
Pages
5399 - 5399
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.